Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Preventing atherosclerotic events with aspirin.

× No keyword cloud information.

14 in total

Review 1. Is aspirin safe for patients with heart failure?

Authors: J G Cleland; C J Bulpitt; R H Falk; I N Findlay; C M Oakley; G Murray; P A Poole-Wilson; C R Prentice; G C Sutton
Journal: Br Heart J Date: 1995-09

Review 2. Anticoagulant and antiplatelet therapy in heart failure.

Authors: J G Cleland
Journal: Curr Opin Cardiol Date: 1997-05 Impact factor: 2.161

3. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial.

Authors:
Journal: Lancet Date: 2000-04-15 Impact factor: 79.321

4. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors:
Journal: BMJ Date: 2002-01-12

Review 5. Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?

Authors: J G Cleland; J John; T Houghton
Journal: Curr Opin Nephrol Hypertens Date: 2001-09 Impact factor: 2.894

6. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs.

Authors: J Weil; M J Langman; P Wainwright; D H Lawson; M Rawlins; R F Logan; T P Brown; M P Vessey; M Murphy; D G Colin-Jones
Journal: Gut Date: 2000-01 Impact factor: 23.059

7. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors:
Journal: BMJ Date: 1994-01-08

8. The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group.

Authors:
Journal: Circulation Date: 1980-12 Impact factor: 29.690

9. Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group.

Authors:
Journal: Circulation Date: 1980-09 Impact factor: 29.690

10. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group.

Authors: K Breddin; D Loew; K Lechner; K Oberla; E Walter
Journal: Circulation Date: 1980-12 Impact factor: 29.690

12 in total

1. Gathering intelligence on antiplatelet drugs: the view from 30 000 feet. When combined with other information overviews lead to conviction.

Authors: Muredach Reilly; Garret A FitzGerald
Journal: BMJ Date: 2002-01-12

Preventing atherosclerotic events with aspirin.

Review 1. Is aspirin safe for patients with heart failure?

Review 2. Anticoagulant and antiplatelet therapy in heart failure.

3. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial.

4. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Review 5. Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?

6. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs.

7. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

8. The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group.

9. Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group.

10. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group.

1. Gathering intelligence on antiplatelet drugs: the view from 30 000 feet. When combined with other information overviews lead to conviction.

2. Article makes simple errors and could cause unnecessary deaths.

3. Antiplatelet therapy and atherosclerotic events. Commentary is inaccurate.

4. Aspirin Use and Mortality in Two Contemporary US Cohorts.

Review 5. Aspirin for the prevention of cardiovascular events in the elderly.

Review 6. Approaches to prevention of cardiovascular complications and events in diabetes mellitus.

Review 7. Secondary prevention of stroke: a practical guide to drug treatment.

8. Changes in drug treatment in the elderly between 1971 and 2000.

9. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity.

10. Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial.